Novartis Ag

Alessandra Vitaliti Garami

Martin E Schwab

Stefan De Buck

Martin Kaul

Carmen Barske

Maciej Cabanski

Stefan Frentzel

Bruno Bieth

Bruno Cenni

Arvind Kinhikar

Andrijana Radivojevic

Souvik Bhattacharya

Anis Khusro Mir

Julian Storim

Anis Khurso Mir

Thomas Severin

The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

The present disclosure relates to methods for treating Sjögren's Syndrome disease using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Sjögren's Syndrome patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor

The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant &#x3c;1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.

Nogo-A binding molecules and pharmaceutical use thereof

The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant&#x3c;1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.

Growing community of inventors

Oberwill, Switzerland

Alessandra Vitaliti Garami